pPACK-SPIKE™ Alpha (B.1.1.7, UK) Variant Lentivector Packaging Mix

Overview

As potentially more transmissible variants of SARS-CoV-2 emerge, understanding how mutations in the spike protein impact SARS-CoV-2 behavior is critical. With the pPACK-SPIKE™ Alpha (B.1.1.7) UK Variant Spike Protein Lentivector Packaging Mix, you can safely characterize the SARS-CoV-2 S1 spike protein from the emerging United Kingdom lineage Alpha (B.1.1.7)—ΔH69/V70, ΔY144, N501Y, A570D, D614G, P681H, T716I, S982A, D1118H. Designed to efficiently package most third-generation lentivectors, the pPACK-SPIKE Alpha (B.1.1.7) UK Variant Spike Protein Lentivector Packaging Mix speeds and simplifies preparation of lentiviral particles pseudotyped with the SARS-CoV-2 ΔH69/V70, ΔY144, N501Y, A570D, D614G, P681H, T716I, S982A, D1118H spike glycoprotein, making it an ideal reagent for vaccine and antiviral drug discovery projects.

Based on SBI’s highly cited pPACKH1 packaging system but with a truncated SARS-CoV-2 ΔH69/V70, ΔY144, N501Y, A570D, D614G, P681H, T716I, S982A, D1118H Spike protein [1] replacing the standard VSV-G envelope protein, the pPACK-SPIKE Alpha (B.1.1.7) UK Variant Spike Protein Packaging Mix consists of three plasmids that produce all of the structural and replication proteins needed to transcribe and package an RNA copy of an expression lentivector into recombinant, ΔH69/V70, ΔY144, N501Y, A570D, D614G, P681H, T716I, S982A, D1118H “Spike” pseudotyped lentiviral particles. As a result, you can conduct a range of SARS-CoV-2 studies under BSL-2 conditions, including neutralization assays, studies of virus interactions with host surface proteins, and the development of vaccines and therapeutics.

For added convenience we also offer pPACK-BALD™, an envelope protein-free lentivector packaging mix that can be used as a negative control for any pPACK-SPIKE study, or for creating lentivirus particles pseudotyped with the envelope protein of your choice.

• Based on SBI’s popular and highly cited pPACKH1 Packaging System
• Uses codon-optimized SARS-CoV-2 “S” protein from UK Variant Alpha (B.1.1.7) in place of VSV-G envelope protein
• Spike protein mutations are ΔH69/V70, ΔY144, N501Y, A570D, D614G, P681H, T716I, S982A, D1118H
• Ideal for vaccine and antiviral efficacy studies under BSL2 conditions
• Package any 3rd-generation lentivector reporter of your choice, including SBI’s popular LentiLabeler reporters
• Compare with our full range of pPACK-SPIKE S protein pseudotyped lentiviruses to better understand emerging variants
• Use with pPACK-BALD™, an envelope protein-free lentivector packaging system that is an ideal negative control

pPACK-SPIKE Alpha (B.1.1.7) UK Variant Spike Protein Lentivector Packaging Mix is available as stand-alone packaging mixes with sufficient plasmids for 10 reactions (standard size) or 25 reactions (XL), as well as in a convenient kit format that includes PureFection™ Transfection Reagent and PEG-it Virus Precipitation Solution.

See all of the available pPACK-SPIKE S protein variants:

1. Ou X, et al. Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. Nat. commun. 2020 Mar 27;11(1):1620. doi: 10.1038/s41467-020-15562-9. PMCID: PMC7100515.